TNYA Stock Analysis: Buy, Sell, or Hold?
TNYA - Tenaya Therapeutics, Inc. Common Stock
$0.79
0.04 (5.50%)
▲
5d:
+10.83%
30d:
-0.39%
90d:
+15.55%
BUY
HIGH Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When TNYA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: TNYA shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: TNYA shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: TNYA is currently trading at $0.79, which is considered slightly high relative to its 30-day fair value range of $0.70 to $0.79. From a valuation perspective, the stock is trading at a discount (Forward PE: -1.9) compared to its historical average (10.3). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TNYA is in a strong uptrend. Immediate support is located at $0.68, while resistance sits at $0.95. The stock is showing strong short-term momentum, up 5.5% recently.
Market Sentiment: TNYA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.00 (+408.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TNYA is in a strong uptrend. Immediate support is located at $0.68, while resistance sits at $0.95. The stock is showing strong short-term momentum, up 5.5% recently.
Market Sentiment: TNYA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.00 (+408.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$0.70 -
$0.79
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
85.7%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.5%)
- BULLISH: Trading 408.3% below Wall St target ($4.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$0.70 -
$0.79
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$0.68
Resistance Level
$0.95
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.90
Wall Street Target
$4.00
(+408.3%)
PE vs Historical
-1.9 vs 10.3
CHEAP
Share & Embed Analysis
Last updated: July 02, 2026 10:48 PM ET
Data refreshes hourly during market hours. Next update: 11:48 PM
Data refreshes hourly during market hours. Next update: 11:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TNYA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Group Gp Lp Column III
SELL
3511826 shares
2026-02-25
Group Gp Lp Column III
SELL
658440 shares
2026-02-24
Faraz Ali
SELL
14862 shares
2026-02-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$106 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 54 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$110 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 45 HOLD |
